PMID- 35083382
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220128
IS  - 2434-0790 (Electronic)
IS  - 2434-0790 (Linking)
VI  - 4
IP  - 1
DP  - 2022 Jan 7
TI  - Comparison of Dasatinib- and Imatinib-Related Cardiotoxic Adverse Events in 
      Japanese Patients With Chronic Myeloid Leukemia and Gastrointestinal Stromal 
      Tumor.
PG  - 1-8
LID - 10.1253/circrep.CR-21-0140 [doi]
AB  - Background: Despite the beneficial effects of BCR-ABL1 tyrosine kinase inhibitors 
      (TKIs) in the treatment of chronic myeloid leukemia (CML), they may also cause 
      adverse events (AEs), especially cardiovascular toxicity. The incidence of 
      TKI-induced AEs may vary among ethnic groups, and there is little specific 
      information for Japanese patients. Methods and Results: Sixty-nine consecutive 
      patients who were started on treatment with dasatinib (n=25) or imatinib (n=44) 
      for CML or gastrointestinal stromal tumor (GIST) between December 2008 and 
      December 2019 were retrospectively recruited to the study. We determined the 
      prevalence of AEs through October 2020 and compared the incidence of AEs between 
      the 2 drugs. Baseline characteristics were comparable between the 2 groups. 
      However, compared with the imatinib-treated group, the dasatinib-treated group 
      had a higher incidence of congestive heart failure (CHF; 20.0% vs. 2.3%; P=0.04), 
      pleural effusion (48% vs. 20.5%; P=0.03), pericardial effusion (24% vs. 4.6%; 
      P=0.02), QT prolongation (4 vs. 0 patients; P=0.02), and pulmonary hypertension 
      (3 vs. 0 patients; P=0.04). In the dasatinib-treated group, CHF tended to be 
      associated with tricuspid valve regurgitation pressure gradient, and pleural 
      effusion was observed in all patients. All-cause mortality and other 
      cardiovascular events did not differ significantly between the 2 groups. 
      Conclusions: Cardiotoxic AEs occurred more frequently in Japanese patients with 
      CML and GIST treated with dasatinib than imatinib.
CI  - Copyright (c) 2022, THE JAPANESE CIRCULATION SOCIETY.
FAU - Motokawa, Tetsufumi
AU  - Motokawa T
AD  - Department of Cardiovascular Medicine, Nagasaki University Graduate School of 
      Biomedical Sciences Nagasaki Japan.
FAU - Ikeda, Satoshi
AU  - Ikeda S
AD  - Department of Cardiovascular Medicine, Nagasaki University Graduate School of 
      Biomedical Sciences Nagasaki Japan.
FAU - Ueno, Yuki
AU  - Ueno Y
AD  - Department of Cardiovascular Medicine, Nagasaki University Graduate School of 
      Biomedical Sciences Nagasaki Japan.
FAU - Eguchi, Masamichi
AU  - Eguchi M
AD  - Department of Cardiovascular Medicine, Nagasaki University Graduate School of 
      Biomedical Sciences Nagasaki Japan.
FAU - Minami, Takako
AU  - Minami T
AD  - Department of Cardiovascular Medicine, Nagasaki University Graduate School of 
      Biomedical Sciences Nagasaki Japan.
FAU - Kawano, Hiroaki
AU  - Kawano H
AD  - Department of Cardiovascular Medicine, Nagasaki University Graduate School of 
      Biomedical Sciences Nagasaki Japan.
FAU - Kobayashi, Kazuma
AU  - Kobayashi K
AD  - Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences 
      Nagasaki Japan.
FAU - Imaizumi, Yoshitaka
AU  - Imaizumi Y
AD  - Department of Hematology, Atomic Bomb Disease and Hibakusya Medicine Unit, Atomic 
      Bomb Disease Institute, Nagasaki University Nagasaki Japan.
FAU - Maemura, Koji
AU  - Maemura K
AD  - Department of Cardiovascular Medicine, Nagasaki University Graduate School of 
      Biomedical Sciences Nagasaki Japan.
LA  - eng
PT  - Journal Article
DEP - 20211116
PL  - Japan
TA  - Circ Rep
JT  - Circulation reports
JID - 101746642
PMC - PMC8710638
OTO - NOTNLM
OT  - Cardiotoxicity
OT  - Congestive heart failure
OT  - Pleural effusion
OT  - Pulmonary hypertension
OT  - QT prolongation
COIS- K.M. is a member of Circulation Reports' Editorial Team. The remaining authors 
      have no conflicts of interest to declare.
EDAT- 2022/01/28 06:00
MHDA- 2022/01/28 06:01
PMCR- 2021/11/16
CRDT- 2022/01/27 05:50
PHST- 2021/10/14 00:00 [received]
PHST- 2021/10/14 00:00 [accepted]
PHST- 2022/01/27 05:50 [entrez]
PHST- 2022/01/28 06:00 [pubmed]
PHST- 2022/01/28 06:01 [medline]
PHST- 2021/11/16 00:00 [pmc-release]
AID - 10.1253/circrep.CR-21-0140 [doi]
PST - epublish
SO  - Circ Rep. 2021 Nov 16;4(1):1-8. doi: 10.1253/circrep.CR-21-0140. eCollection 2022 
      Jan 7.